Abacavir Sulfate, known as Ziagen, is a drug with a controversial drug development history and the focus of extensive patent litigation. Glaxo SmithKline is the patent holder of this medicine. Abacavir is one of the most highly recommended HIV drugs available today. After the filing of the opposition, this patent was withdrawn in India and generic versions of the drug remained on the market. Since the decision, both generic and originator prices have come down significantly between 2006-2009. Read more HERE.
"Bitter Pills", a history of Abacavir
I-MAK Patent Opposition
Indian pre-grant patent opposition [pdf]